FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

wasinington,	D.O. 20040	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Guerin Mark Patrick						2. Issuer Name and Ticker or Trading Symbol Onconova Therapeutics, Inc. [ ONTX ]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (speci				
(Last)	(First) (Middle) DNCONOVA THERAPEUTICS, INC					3. Date of Earliest Transaction (Month/Day/Year) 03/13/2024											below) CFO AND COO			
12 PENNS TRAIL					4. li	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	•					
(Street) NEWTO	WN PA	A	18940													_	filed by Mo		orting Person One Repo	
(City)	(S	tate)	(Zip)		Rı	ıle ′	10b	5-1(c	;) T	ransa	acti	ion Inc	dicati	on						
												nction was i					on or writter	n plan t	hat is intende	ed to
		Tab	le I - Nor	n-Deriv	vative	Sec	curiti	ies Ad	cqu	ıired, [	Disp	posed o	of, or	Ben	eficial	ly Owne	d			
Date			2. Trans Date (Month		ar) E	2A. Deemed Execution Date, if any (Month/Day/Year		Ė	3. Transac Code (II 8)	Dispose	4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			Benefic Owned	es ally Following	Form (D) o	n: Direct or Indirect ostr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
										Code	v	Amount	(A) or (D) Pr		Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			(1115tr. 4)
Common	Common Stock 03/13				3/202	/2024				M		8,66	6 A		(1)	38,567			D	
Common	Stock			03/1	4/202	4				F		2,59	1	D	\$0.9	35	,976 D			
		Т	able II -									osed of onverti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transa Code ( 8)				Ex	Date Exe piration onth/Day	Date		Amou Secur Under Deriva	7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactie (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Da Ex	ite ercisable		xpiration ate	Title		Amount or Number of Shares					
Restricted Stock	(1)	03/13/2024			M			8,666		(2)		(2)	Comn		8,666	\$0	17,33	4	D	

## Explanation of Responses:

- 1. Restricted stock units convert into common stock on a one-for-one basis.
- 2. On March 13, 2023 the reporting person was granted 26,000 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.

/s/ Mark Guerin

03/15/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.